The Pathology according to p53 Pathway

Area of Science:

• Pathology
• Genomic Oncology
• Molecular Biology

Background:

• Cancer diagnosis traditionally relies on microscopic observation of morphological characteristics.
• Molecular analyses investigate oncogenic pathway activation, genetic mutations, and protein expression for therapeutic targets.
• The p53 pathway is frequently dysregulated in cancer, impacting over half of all cancer cases.

Purpose of the Study:

• To review cardinal biomarkers of the p53 pathway (p53, p16, MDM2).
• To contextualize these biomarkers within traditional surgical pathology and emerging genomic oncology.
• To describe a model for classifying p53 pathway gene status and a minimal immunohistochemical panel.

Main Methods:

• Literature review of p53 pathway biomarkers.
• Integration of traditional histopathology with genomic oncology principles.
• Description of a four-classification immunophenotype model for p53 pathway gene status.

Main Results:

• The p53 pathway, including p53, p16, and MDM2, is crucial in cancer pathogenesis.
• Specific tumor types exhibit high frequencies of p53 pathway gene abnormalities.
• A minimal immunohistochemical panel can aid in assessing p53 pathway status.

Conclusions:

• Interpreting oncogenic signals via immunohistochemistry requires integration with molecular findings from genomic oncology.
• Understanding p53 pathway dysregulation offers diagnostic and therapeutic opportunities.
• Combining morphological and molecular data enhances cancer diagnosis and treatment strategies.